ATCOR Medical, Datacubed Health Partner on Patient Retention and Engagement
Collaboration to focus on digital vascular biomarker patient monitoring trial.
ATCOR Medical, a medical device developer, and Datacubed Health, an eClinical technology provider, announced a joint venture aimed to conduct trial monitoring across therapeutic programs. The teams will employ the recently FDA-approved Conneqt Pulse, a vascular biomarker device, to non-invasively provide advanced arterial health biomarkers.
ATCOR’s device tracks digital biomarkers and sends customized alerts if vascular biometrics fall within a critical range during the trial. ATCOR credits Conneqt with providing clinicians the opportunity to reduce the likelihood of adverse events. Through customized alerts programmed to alert both patients and clinicians of any potential issue, preventing an adverse event becomes more achievable.
“We are thrilled to partner with Datacubed Health and expand what is possible to elevate the patient experience and unlock the power of our digital vascular biomarkers as tools to monitor patient safety. Together we are truly personalizing decentralized trials,” stated Kimberly Tully, managing director, clinical trials partnerships, ATCOR Medical.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
